Purdue Pharma now has FDA permission to market highly controversial opioid painkiller OxyContin to an even younger population. Late last week, the agency green-lighted the drug in patients aged 11 to 16 who haven't benefited enough from alternative therapies. The warnings and precautions for pediatric patients are the same as those for adults, the FDA said. More